Lupin’s collaboration with Honeywell marks a significant leap in the evolution of respiratory care through the adoption of Solstice® Air (HFO-1234ze cGMP) – a next-generation, environmentally sustainable propellant. Unlike traditional hydrofluorocarbon (HFC)-based propellants used in pressurized metered-dose inhalers (pMDIs), Solstice Air boasts ultra-low global warming potential (GWP), reducing greenhouse gas emissions by up to 99.9%. This innovative shift not only supports regulatory goals for environmental sustainability but also reflects the pharmaceutical industry's growing commitment to eco-conscious health solutions.

The integration of Solstice Air into Lupin’s inhalers ensures that patients with asthma and chronic obstructive pulmonary disease (COPD) continue receiving effective treatment while dramatically minimizing environmental impact. As the first pharmaceutical company in India to scale the use of Honeywell’s novel propellant, Lupin is setting a benchmark for sustainable pharmaceutical manufacturing and product innovation. The move could potentially catalyze industry-wide adoption of greener respiratory therapies in both emerging and developed markets.

This partnership represents more than technological progress—it is a strategic step toward aligning public health initiatives with environmental responsibility. By embracing cutting-edge propellant technology, Lupin is enhancing patient care while contributing to global climate objectives. As the companies finalize the deal, the collaboration stands to redefine industry standards for respiratory drug delivery and pave the way for a future where sustainability and health innovation go hand in hand.

MedTech Spectrum's Summary

Innovative Green Technology: Lupin is adopting Honeywell’s Solstice® Air, a next-generation, low-global-warming propellant (HFO-1234ze cGMP), to develop environmentally sustainable inhalers—cutting greenhouse gas emissions by up to 99.9%.

Pioneering Industry Leadership: Lupin becomes the first Indian pharmaceutical company to scale the use of this eco-friendly propellant in pMDIs, setting a new benchmark in sustainable respiratory care.

Balancing Health & Environment: The collaboration delivers effective treatment for asthma and COPD patients while significantly reducing the environmental footprint, aligning public health innovation with climate-conscious practices.